Alumis (ALMS) Expected to Post Quarterly Earnings on Thursday

Key Points

• Alumis is expected to report Q3 2026 results on November 12, with analysts forecasting a loss of $0.73 per share and revenue of $1.90 million.
• In its prior quarter, Alumis reported a $1.11-per-share loss and $1.66 million in revenue, missing analyst expectations on both measures.
• Analysts have a “Moderate Buy” consensus rating and a $33.27 average price target, despite recent rating downgrades; shares opened at $6.55 and have traded between $4.40 and $31.35 over the past year.

Alumis (NASDAQ:ALMS - Get Free Report) is expected to issue its Q3 2026 resultson Thursday, November 12th. Analysts expect Alumis to announce earnings of ($0.73) per share and revenue of $1.90 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The firm had revenue of $1.66 million for the quarter, compared to analysts' expectations of $3.65 million. On average, analysts expect Alumis to post ($2.95) EPS for the current fiscal year and ($2.84) EPS for the next fiscal year.

Alumis Trading Up 0.8%

ALMS opened at $6.55 on Thursday. The stock has a 50-day moving average price of $8.82 and a 200-day moving average price of $21.14. Alumis has a 12-month low of $4.40 and a 12-month high of $31.35.

Analyst Ratings Changes

A number of brokerages recently weighed in on ALMS. Weiss Ratings cut Alumis from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, October 27th. Wall Street Zen lowered Alumis from a "hold" rating to a "sell" rating in a research note on Saturday, September 5th. HC Wainwright reissued a "buy" rating on shares of Alumis in a research note on Monday, October 5th. Wells Fargo & Company decreased their price target on shares of Alumis from $51.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, September 2nd. Finally, Guggenheim lowered shares of Alumis from a "buy" rating to a "neutral" rating in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $33.27.

Insider Activity

In related news, Director Srinivas Akkaraju acquired 546,581 shares of Alumis stock in a transaction dated Tuesday, September 8th. The shares were purchased at an average cost of $10.63 per share, with a total value of $5,810,156.03. Following the completion of the purchase, the director owned 4,937,026 shares of the company's stock, valued at $52,480,586.38. This represents a 12.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 99,754 shares of company stock worth $1,037,804 over the last quarter. 33.70% of the stock is currently owned by company insiders.

Alumis Company Profile

Alumis NASDAQ: ALMS is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company's research is centered on selective modulation of the immune system, with the goal of providing effective, convenient treatments that may address conditions inadequately served by existing therapies.

Its lead product candidate, ESK-001, is an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor designed to selectively regulate signaling pathways involved in inflammatory and autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.